ResMed Competitors

ResMed (NYSE:RMD) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Insider & Institutional Ownership

69.4% of ResMed shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 1.3% of ResMed shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

ResMed has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for ResMed and Abbott Laboratories, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Abbott Laboratories has a consensus target price of $115.3750, indicating a potential upside of 5.59%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than ResMed.

Profitability

This table compares ResMed and Abbott Laboratories' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ResMed and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than ResMed. Abbott Laboratories is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Dividends

ResMed pays an annual dividend of $1.56 per share and has a dividend yield of 0.7%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. ResMed pays out 32.8% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 7 consecutive years and Abbott Laboratories has raised its dividend for 48 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Abbott Laboratories beats ResMed on 10 of the 17 factors compared between the two stocks.

ResMed (NYSE:RMD) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Volatility and Risk

ResMed has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

69.4% of ResMed shares are held by institutional investors. Comparatively, 79.9% of Medtronic shares are held by institutional investors. 1.3% of ResMed shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

ResMed pays an annual dividend of $1.56 per share and has a dividend yield of 0.7%. Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. ResMed pays out 32.8% of its earnings in the form of a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 7 consecutive years and Medtronic has raised its dividend for 43 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current recommendations for ResMed and Medtronic, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Medtronic has a consensus target price of $118.1538, indicating a potential upside of 6.47%. Given Medtronic's stronger consensus rating and higher probable upside, analysts plainly believe Medtronic is more favorable than ResMed.

Profitability

This table compares ResMed and Medtronic's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ResMed and Medtronic's gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than ResMed. Medtronic is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

Medtronic beats ResMed on 10 of the 18 factors compared between the two stocks.

ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Risk & Volatility

ResMed has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Insider & Institutional Ownership

69.4% of ResMed shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 1.3% of ResMed shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dividends

ResMed pays an annual dividend of $1.56 per share and has a dividend yield of 0.7%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. ResMed pays out 32.8% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 7 consecutive years and Stryker has raised its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ResMed and Stryker, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Stryker has a consensus target price of $221.44, indicating a potential downside of 4.97%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than ResMed.

Profitability

This table compares ResMed and Stryker's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ResMed and Stryker's revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than ResMed. Stryker is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats ResMed on 13 of the 18 factors compared between the two stocks.

ResMed (NYSE:RMD) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

ResMed has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Institutional & Insider Ownership

69.4% of ResMed shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 1.3% of ResMed shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ResMed and Intuitive Surgical, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Intuitive Surgical has a consensus target price of $718.2778, indicating a potential downside of 0.11%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than ResMed.

Profitability

This table compares ResMed and Intuitive Surgical's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ResMed and Intuitive Surgical's gross revenue, earnings per share and valuation.

Intuitive Surgical has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats ResMed on 12 of the 14 factors compared between the two stocks.

ResMed (NYSE:RMD) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Risk & Volatility

ResMed has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

69.4% of ResMed shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 1.3% of ResMed shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dividends

ResMed pays an annual dividend of $1.56 per share and has a dividend yield of 0.7%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. ResMed pays out 32.8% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 7 consecutive years and Becton, Dickinson and has raised its dividend for 49 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ResMed and Becton, Dickinson and, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than ResMed.

Profitability

This table compares ResMed and Becton, Dickinson and's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ResMed and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than ResMed. Becton, Dickinson and is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats ResMed on 13 of the 18 factors compared between the two stocks.

ResMed (NYSE:RMD) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

ResMed has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Institutional & Insider Ownership

69.4% of ResMed shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 1.3% of ResMed shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ResMed and Edwards Lifesciences, as reported by MarketBeat.

ResMed presently has a consensus target price of $189.40, indicating a potential downside of 9.62%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than ResMed.

Profitability

This table compares ResMed and Edwards Lifesciences' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ResMed and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats ResMed on 11 of the 14 factors compared between the two stocks.